Ontology highlight
ABSTRACT:
SUBMITTER: Stadler WM
PROVIDER: S-EPMC4696031 | biostudies-literature | 2014 Apr
REPOSITORIES: biostudies-literature
Stadler Walter M WM Vaughn David J DJ Sonpavde Guru G Vogelzang Nicholas J NJ Tagawa Scott T ST Petrylak Daniel P DP Rosen Peter P Lin Chia-Chi CC Mahoney John J Modi Sanjiv S Lee Peter P Ernstoff Marc S MS Su Wu-Chou WC Spira Alexander A Pilz Korinna K Vinisko Richard R Schloss Charles C Fritsch Holger H Zhao Charles C Carducci Michael A MA
Cancer 20131211 7
<h4>Background</h4>Polo-like kinases (Plks) control multiple steps during the cell cycle, and Plk1 is overexpressed in urothelial cancer (UC). Volasertib (BI 6727), a Plk inhibitor, has demonstrated antitumor activity in several malignancies, including UC. In this phase 2 trial, the authors investigated volasertib as a second-line treatment in advanced/metastatic UC.<h4>Methods</h4>Patients who progressed within 2 years of 1 prior chemotherapy regimen received 300 mg volasertib on day 1 every 3 ...[more]